In these patients, five genes were differentially expressed, in addition to ABCG2, SLC51B and ABCC1 also genes SLC51A and SLCO1B3. Similarly to in patients with FIGO IA stage, low-grade tumours and patients with ≤50% invasion into the myometrium also in patients without LVI gene SLC51A was up-regulated (1.5-fold), while gene SLC51B was down-regulated (2.7-fold) in EC versus control tissue. This evidence concerns the gene SLC51A and neoplasm.